WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 407152
Description: SR9243 is a potent and selective LXR inverse agonist. SR9243 kills cancer cells by inhibiting lipid production and the Warburg effect. SR9243 induces cell death in multiple types of cancer and does not cause the side effects that have derailed previous attempts to target these processes. In cancer cells, SR9243 significantly inhibited the Warburg effect and lipogenesis by reducing glycolytic and lipogenic gene expression. SR9243 induced apoptosis in tumors without inducing weight loss, hepatotoxicity, or inflammation. Malignant cells exhibit aerobic glycolysis (the Warburg effect) and become dependent on de novo lipogenesis, which sustains rapid proliferation and resistance to cellular stress.
MedKoo Cat#: 407152
Chemical Formula: C31H32BrNO4S2
Exact Mass: 625.09561
Molecular Weight: 626.62
Elemental Analysis: C, 59.42; H, 5.15; Br, 12.75; N, 2.24; O, 10.21; S, 10.23
SR9243, purity > 98%, is in stock. The same day shipping after order is received.
Synonym: SR9243; SR-9243; SR 9243.
IUPAC/Chemical Name: N-(3-bromophenethyl)-2,4,6-trimethyl-N-((3'-(methylsulfonyl)-[1,1'-biphenyl]-4-yl)methyl)benzenesulfonamide
InChi Key: InChI=1S/C31H32BrNO4S2/c1-22-17-23(2)31(24(3)18-22)39(36,37)33(16-15-25-7-5-9-29(32)19-25)21-26-11-13-27(14-12-26)28-8-6-10-30(20-28)38(4,34)35/h5-14,17-20H,15-16,21H2,1-4H3
InChi Code: FYQFEJFTCLKXTQ-UHFFFAOYSA-N
SMILES Code: O=S(C1=C(C)C=C(C)C=C1C)(N(CCC2=CC=CC(Br)=C2)CC3=CC=C(C4=CC=CC(S(=O)(C)=O)=C4)C=C3)=O
The following data is based on the product molecular weight 626.62 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: New Compound Targets Warburg Effect. Cancer Discov. 2015 Sep;5(9):898. doi:
10.1158/2159-8290.CD-NB2015-108. Epub 2015 Jul 24. PubMed PMID: 26209538.
2: Flaveny CA, Griffett K, El-Gendy Bel-D, Kazantzis M, Sengupta M, Amelio AL,
Chatterjee A, Walker J, Solt LA, Kamenecka TM, Burris TP. Broad Anti-tumor
Activity of a Small Molecule that Selectively Targets the Warburg Effect and
Lipogenesis. Cancer Cell. 2015 Jul 13;28(1):42-56. doi:
10.1016/j.ccell.2015.05.007. Epub 2015 Jun 25. PubMed PMID: 26120082.